Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Editas Medicine Fell as Much as 11.8% Today

By Maxx Chatsko - Mar 9, 2020 at 4:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene-editing pioneer is getting caught in the broader market correction, which isn't too surprising considering the stock's big gains last week.

What happened

Shares of Editas Medicine (EDIT -1.49%) fell nearly 12% today as part of a broader market correction. Last week, investors were growing increasingly worried about the economic impact of efforts to contain regional coronavirus outbreaks. This week, they'll have to add an oil price war between Saudi Arabia and Russia to the mix.

There's no news specific to Editas Medicine today. However, shares of the gene-editing pioneer jumped last week after the company announced the first patient had been dosed with its in vivo engineering tools. That made it a prime candidate for a correction, which is what's happening today.

As of 3:53 p.m. EDT, the pharma stock had settled to a 10.7% loss.

A roller coaster.

Image source: Getty Images.

So what

On March 4, Editas Medicine and Allergan announced that the first patient had been dosed in a phase 1/2 trial evaluating EDIT-101 as a potential treatment for Leber congenital amaurosis 10 (LCA10), the most common form of the disease that most commonly causes inherited childhood blindness.

The announcement marked the first time an in vivo gene editing tool had been used in an individual. In vivo tools are injected into a patient and work directly on tissues in the body. Ex vivo tools work on cells harvested from the body in a controlled setting, and the engineered cells are then reintroduced into the body. Before this development, only ex vivo tools had progressed into clinical trials.

It was a first for CRISPR gene editing, but a relatively meaningless milestone in the grand scheme of things. After all, the phase 1/2 trial in question will enroll 18 individuals. That helps to explain why shares are falling today. 

Now what

There's not much investors can do during a market correction, although remaining calm and maintaining a long-term mindset are two must-dos. Investors will now have to wait for more meaningful updates from Editas Medicine and its pipeline, which includes intriguing programs in oncology, cell therapies, and blood disorders. Considering the company began 2020 with roughly $457 million in cash, it's well positioned to advance additional assets into clinical trials in the next two years. That also suggests today's move is unlikely to be very memorable in the long run. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$19.13 (-1.49%) $0.29
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.